A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)

NCT06521554 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

200

Enrollment

INDUSTRY

Sponsor class

Conditions

Locally Advanced Solid Tumor
Metastatic Solid Tumor

Interventions

DRUG: NVL-330

Sponsor

Nuvalent Inc.